Across TCGA pan-cancer cohorts, TRAV12-2 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TRAV12-2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TRAV12-2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TRAV12-2 is over-expressed in tumor, although a few such as COAD and BLCA show the opposite, repressed pattern.

KIRC, COAD, and BRCA are the cancer types where TRAV12-2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRAV12-2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+1.422	<.001	12	view →
COAD	All	IV	−1.004	.005	6	view →
BRCA	All	All	+0.305	.023	3	view →
BLCA	Female	All	−0.883	.047	2	view →
LUSC	All	All	−0.505	.005	2	view →
UCEC	All	All	−0.423	.044	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: TRAV12-2 RNA expression & survival · all TRAV12-2 data types